Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Approximately 6-7 million people around the world are estimated to be infected with Trypanosoma cruzi, the causative agent of Chagas disease. The current treatments are inadequate and therefore new medical interventions are urgently needed. In this paper we describe the identification of a series of disubstituted piperazines which shows good potency against the target parasite but is hampered by poor metabolic stability. We outline the strategies used to mitigate this issue such as lowering logD, bioisosteric replacements of the metabolically labile piperazine ring and use of plate-based arrays for quick diversity scoping. We discuss the success of these strategies within the context of this series and highlight the challenges faced in phenotypic programs when attempting to improve the pharmacokinetic profile of compounds whilst maintaining potency against the desired target. Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.


Kate McGonagle, Gary J Tarver, Juan Cantizani, Ignacio Cotillo, Peter G Dodd, Liam Ferguson, Ian H Gilbert, Maria Marco, Tim Miles, Claire Naylor, Maria Osuna-Cabello, Christy Paterson, Kevin D Read, Erika G Pinto, Jennifer Riley, Paul Scullion, Yoko Shishikura, Frederick Simeons, Laste Stojanovski, Nina Svensen, John Thomas, Paul G Wyatt, Pilar Manzano, Manu De Rycker, Michael G Thomas. Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease. European journal of medicinal chemistry. 2022 Aug 05;238:114421

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35594652

View Full Text